Search research articles
Contact Us
Filters
Showing results (171-180 of 357) with videos related to
Page
of 36
Sort By:
Cancer Treatment Reviews
|
June 24, 2020
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Mélanie Claps, Alessia Mennitto, Valentina Guadalupi, et al.
Clinical Genitourinary Cancer
|
May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity
Joaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
Oncology
|
October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)
Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
The Oncologist
|
October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial
Neal D Shore, Maha Hussain, Fred Saad, et al.
European Urology
|
November 8, 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Guru Sonpavde, Toni K Choueiri, Bernard Escudier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
European Urology
|
March 12, 2014
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review
Guillaume Ploussard, Siamak Daneshmand, Jason A Efstathiou, et al.
Clinical Genitourinary Cancer
|
October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
Cora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
Page
of 36
Search research articles
Search
Showing results (171-180 of 357) with videos related to
Sort By:
Page
of 36
Cancer Treatment Reviews
|
June 24, 2020
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Mélanie Claps, Alessia Mennitto, Valentina Guadalupi, et al.
Clinical Genitourinary Cancer
|
May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity
Joaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
Oncology
|
October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)
Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
The Oncologist
|
October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial
Neal D Shore, Maha Hussain, Fred Saad, et al.
European Urology
|
November 8, 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Guru Sonpavde, Toni K Choueiri, Bernard Escudier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
European Urology
|
March 12, 2014
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review
Guillaume Ploussard, Siamak Daneshmand, Jason A Efstathiou, et al.
Clinical Genitourinary Cancer
|
October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
Cora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
Page
of 36